|
| related topics |
| {product, candidate, development} |
| {product, liability, claim} |
| {operation, natural, condition} |
| {regulation, government, change} |
| {property, intellectual, protect} |
| {interest, director, officer} |
| {acquisition, growth, future} |
| {tax, income, asset} |
| {condition, economic, financial} |
| {cost, operation, labor} |
| {customer, product, revenue} |
|
|
We plan to increase the size of our U.S. direct sales force
We may not be able to adequately enforce or protect our intellectual property rights or to protect ourselves against the infringement claims of others.
Our failure to obtain regulatory clearance/approval and maintain regulatory compliance for any of our products would impact our ability to generate revenue from those products.
Because our biomaterial products are manufactured from bovine pericardium, perceptions about Bovine Spongiform Encephalopathy may impact our sales.
We may face the risk of product liability claims and product recalls that could result in costly and time consuming litigation and significant liability.
Due to the unpredictability of the health care industry, our customers may not be able to receive third party reimbursement for the medical procedures utilizing our products.
The current global economic downturn could adversely impact our business.
A portion of our investment portfolio is invested in auction rate securities and failures in these auctions may affect our liquidity, and also may require us to record an other-than-temporary impairment charge in our income statement.
We depend on highly specialized equipment to manufacture our products and loss of or damage to our manufacturing facility could result in significant losses.
We cannot predict the outcome of our clinical trials.
Our strategy to acquire complementary businesses and technologies involves risk and may result in disruptions to our business by, among other things, distracting management time and diverting financial resources.
We may be obligated to indemnify the purchaser or our former interventional business for certain material adverse events that may arise.
Full 10-K form ▸
|
|
| related documents |
| 780127--1/4/2008--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 1015155--3/10/2006--CHARLES_&_COLVARD_LTD |
| 1114200--2/28/2007--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 806517--3/27/2009--PSYCHEMEDICS_CORP |
| 1436083--7/20/2009--New_Millennium_Products |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 1101026--5/18/2009--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 899866--2/23/2009--ALEXION_PHARMACEUTICALS_INC |
| 949858--3/16/2006--SONUS_PHARMACEUTICALS_INC |
| 1137411--11/23/2010--ROCKWELL_COLLINS_INC |
| 28626--9/13/2006--LIFECORE_BIOMEDICAL_INC |
| 911649--3/31/2006--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 27096--9/12/2007--DATASCOPE_CORP |
| 1114200--3/1/2010--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 1137411--11/25/2008--ROCKWELL_COLLINS_INC |
| 29332--3/3/2010--DIXIE_GROUP_INC |
| 877476--3/8/2010--AMERICA_SERVICE_GROUP_INC_/DE |
| 1282543--3/30/2010--AFFIRMATIVE_INSURANCE_HOLDINGS_INC |
| 27096--9/13/2006--DATASCOPE_CORP |
| 1092791--7/28/2010--PACIFIC_LAND_&_COFFEE_CORP |
| 96943--2/25/2009--TELEFLEX_INC |
| 1012019--3/12/2010--RUSH_ENTERPRISES_INC_\TX\ |
| 9092--2/23/2010--BADGER_METER_INC |
| 721371--8/27/2009--CARDINAL_HEALTH_INC |
| 1050825--4/24/2009--STEELCASE_INC |
| 1123361--3/6/2007--VIASYS_HEALTHCARE_INC |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 880432--9/28/2007--MISONIX_INC |
| 880432--9/28/2006--MISONIX_INC |
|